Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

TenNor Therapeutics (丹诺医药) IPO: Rich Valuation for an Antibacterial Deal

TenNor Therapeutics (丹诺医药) Pre-IPO: AP Updates and Further Research

TeNor Therapeutics (丹诺医药) Pre-IPO Quick Comment: Strong Innovation Constrained by Commercial Outlook

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

TenNor Therapeutics (Suzhou) Limited / Equity Capital Markets

TenNor Therapeutics (Suzhou) Limited (TEN123 HK)

<ul>
<li>TenNor Therapeutics raised HKD 598.3m (USD 76.9m) from its global offering and will list on the Hong Kong Stock Exchange on Friday, May 22, 2026.</li>
<li>In our previous notes, we looked at the company's fundamentals and the valuation.</li>
<li>In this note, we provide an update for the IPO before its trading debut.</li>
</ul>


TenNor Therapeutics raised HKD 598.3m (USD 76.9m) from its global offering and will list on the Hong Kong Stock Exchange on Friday, May 22, 2026.
In our previous notes, we looked at the company's fundamentals and the valuation.
In this note, we provide an update for the IPO before its trading debut.


TenNor Therapeutics (丹诺医药) IPO Trading